Sharing Our Strength: A Research Study for Bone Marrow/Stem Cell Transplant Survivors

Multiple Myeloma Clinical Trial

Official title:

Sharing Our Strength: A Research Study for Bone Marrow/Stem Cell Transplant Survivors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00701844
• Other study ID #: GCO #06-0391 (2)
• Secondary ID: RSGPB-07-285-01-
• Status: Completed
• Phase: N/A
• First received: June 4, 2008
• Last updated: November 14, 2017
• Start date: July 2007
• Est. completion date: September 2011

Study information

• Verified date: May 2013
• Source: University of North Carolina, Chapel Hill
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The Sharing Our Strength study is being conducted to help us understand people's experiences with hematopoietic stem cell transplantation and to test a new program designed to help people recover physically and emotionally after transplant.

Description:

This is a study for survivors of hematopoietic stem cell transplantation (also known as bone marrow transplant), which is an intensive medical treatment for cancers such as leukemia, lymphoma, and multiple myeloma as well as other diseases. Because it is a physically and emotionally demanding treatment, many people report having ongoing physical and emotional difficulties after having a transplant. The Sharing Our Strength study is being conducted to help us understand people's transplant experiences and to test a new program designed to help them recover physically and emotionally after transplant. All parts of the study are completed by mail and telephone. Participants will receive compensation for their time.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 315
• Est. completion date: September 2011
• Est. primary completion date: September 2011
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Be a transplant survivor who is 9 months to 3 years beyond transplant and not currently relapsed. and not currently relapsed

• Be at least 18 years old now (and at least 16 when they had their transplant)

• Speak English

• Have telephone service

Exclusion Criteria:

Related Conditions & MeSH terms

• Acute Leukemia
• Acute Lymphocytic Leukemia
• Hematological Cancers
• Leukemia
• Leukemia, Lymphoid
• Multiple Myeloma
• Neoplasms, Plasma Cell
• Precursor Cell Lymphoblastic Leukemia-Lymphoma
• Psychological Distress

Intervention

Behavioral:
• Writing A (Experimental informative writing)
Experimental informative writing
• Writing B (Experimental noninformative writing)
Experimental noninformative writing
• Writing C (Control informative writing)
Control informative writing
• Writing D (Control noninformative writing)
Control noninformative writing

Locations

Country	Name	City	State
United States	University of North Carolina at Chapel Hill	Chapel Hill	North Carolina
United States	Hackensack University Medical Center	Hackensack	New Jersey
United States	Mount Sinai School of Medicine	New York	New York

Sponsors (2)

Lead Sponsor	Collaborator
University of North Carolina, Chapel Hill	American Cancer Society, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Psychological Adjustment		At screening, baseline and 3 months following intervention
Secondary	Quality of Life		At screening, baseline and 3 months following intervention